In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Crude awakening: Kapoor’s renewable-material protest art installed on Shell gas platform
In the North Sea, protest art made by Anish Kapoor, using renewable materials such as used coffee grounds and beetroot powder, has been installed...
Tiny Vinyl to release tiny, biobased PVC records
In the US, a startup called Tiny Vinyl has created cute, mini, vinyl records out of bio-attributed polyvinyl chloride. The 4-inch mini singles play...
Fun with Fungi: Japanese designers create mycelium block-growing kit
In Japan, designers have created a biomaterial kit for growing toy blocks out mycelium. Dubbed MYMORI, the kit includes block molds and a mycelium...